Medically reviewed by Eland Siddle, PharmD · Last updated July 2026
Pharmacogenomics is the study of how a person's genes influence how they respond to medications. Different people can take the same drug at the same dose and experience very different results: one person gets the expected benefit, another sees little effect, and a third has a serious side effect. In many cases, the difference comes down to genetics.
The name combines "pharmacology" (the science of drugs) and "genomics" (the study of genes). In plain terms, it answers the question: given this child's DNA, how will their body handle this medication?
For parents, pharmacogenomics matters because children are not small adults. Their metabolic pathways are still developing, and a genetic variant that changes how a drug is processed can have a bigger impact in a child than in a grown adult. Knowing about these variants before a prescription is written gives doctors more information to work with.
How genes affect drug metabolism
Most medications are broken down, metabolized, by enzymes in the liver. Several of these enzymes are encoded by genes, and common variants in those genes change how quickly or efficiently the enzymes work. The three gene families that come up most often in pediatric pharmacogenomics are CYP2D6, CYP2C19, and TPMT.
CYP2D6
CYP2D6 encodes an enzyme responsible for metabolizing a wide range of medications, including certain pain relievers, antidepressants, and ADHD medications. Variants in this gene fall into four general categories:
- Poor metabolizers break down the drug slowly, so it can build up and cause side effects.
- Intermediate metabolizers process the drug more slowly than average, which may reduce effectiveness or increase risk at standard doses.
- Normal (extensive) metabolizers process the drug as expected.
- Ultrarapid metabolizers break the drug down so quickly that standard doses may not reach a therapeutic level, or, for prodrugs that are activated by CYP2D6, may convert too much at once.
CYP2C19
CYP2C19 is involved in metabolizing medications used for conditions ranging from acid reflux to anxiety and certain antifungal treatments. Like CYP2D6, variants can make someone a poor, intermediate, normal, or ultrarapid metabolizer. A child who is a poor CYP2C19 metabolizer may have a very different experience with a standard prescription than a child who is a normal metabolizer, at the same dose.
TPMT
TPMT encodes an enzyme that metabolizes a class of drugs called thiopurines, which are used to treat certain cancers and autoimmune conditions. Reduced TPMT activity is well established as a risk factor for serious toxicity when thiopurines are prescribed at standard doses. Testing for TPMT variants before starting thiopurine therapy is already standard practice in many oncology settings, making it one of the clearest examples of pharmacogenomics in routine clinical use.
Why pharmacogenomics matters specifically for children
Children are prescribed medications across nearly every therapeutic category: antibiotics, pain management after surgery, medications for ADHD, antiepileptics, chemotherapy, and more. Because children's bodies change so rapidly during development, the stakes around dosing accuracy are high.
A few reasons pharmacogenomics deserves particular attention in pediatrics:
- First prescriptions happen early. Many children receive their first significant medication during a time when their metabolism is already unpredictable due to age. A genetic variant on top of developmental variability compounds that uncertainty.
- Children can't always describe what they're feeling. An infant or toddler experiencing a drug side effect can't say "this feels wrong." Unexplained irritability, poor feeding, or unusual sedation may be the only signals.
- Preventive information is more actionable than reactive testing. Knowing a child's pharmacogenomic profile before a prescription is written means the prescribing physician already has the information. Testing after an adverse event is still useful, but acting on information in advance is generally better for the child.
For a deeper look at how specific gene variants shape medication outcomes in children, this article on how your child's genes affect medication response walks through the mechanisms in more detail.
Pharmacogenomics vs. standard prescribing: a comparison
| Approach | Basis for dosing | Accounts for genetic variation | Timing |
|---|---|---|---|
| Standard prescribing | Age, weight, diagnosis | No | At point of prescription |
| Pharmacogenomics-informed prescribing | Age, weight, diagnosis, plus genetic metabolizer status | Yes | Before first prescription (ideally) |
Standard prescribing works well for most children most of the time. Pharmacogenomics adds a layer of precision for cases where metabolizer status is clinically relevant, which is more common than many parents realize. The MedlinePlus overview of pharmacogenomics is a reliable starting point if you want to explore the science further.
What pharmacogenomics does not do
It is worth being clear about the limits. Pharmacogenomics tells you about a person's metabolic tendencies for specific drug-gene pairs that have been studied. It does not predict every possible drug reaction, it does not replace the clinical judgment of a prescribing physician, and it does not guarantee a particular outcome with any medication. It is one input, an increasingly useful one, in a larger clinical picture.
If you have concerns about a specific medication your child has been prescribed, the right next step is a conversation with their physician or a genetic counselor who can review the results in context.
Where Fore fits
Fore's at-home pediatric genetic health screen uses whole genome sequencing to analyze over 100 medication interactions alongside 1,000+ genetic conditions. That means pharmacogenomic information is included as part of a single cheek swab, with no separate test or clinic visit required.
Because whole genome sequencing captures the full genome rather than a limited panel, Fore's screen covers a broader range of drug-gene pairs than many targeted pharmacogenomics tests. Results are reviewed with board-certified genetic counseling, so families receive context alongside the data. And because the genome is stored and reanalyzed over time, pharmacogenomic findings can be updated as new drug-gene associations are established, without collecting a new sample.
For more on how genetic testing fits into a broader picture of pediatric health, see what whole genome sequencing actually covers and what a genetic counselor does with the results.
Ready to learn what your child's genome can reveal? Explore Fore's at-home screen.
Personalized Care, Not Prediction
Pharmacogenomics isn't just interesting science. It changes how safely a child can be treated.
Traditional medicine tends to ask one question: is my child sick? Fore is built around a different one: how do we help keep them healthy? That shift matters, because a genetic finding is not a diagnosis.
- A variant is not a verdict. Most children who carry one will never develop the associated condition.
- It points to personalized care, not a fixed fate. A finding identifies who may benefit from closer attention, not who is destined to get sick.
- It gives your pediatrician a head start. Depending on the finding, that can mean earlier eye or hearing exams, periodic heart monitoring, earlier cholesterol screening, avoiding a specific medication, or simply noting the result to watch over time.
- The goal isn't predicting the future. It's making your child's care more personalized from day one.
Fore's at-home whole genome screen covers 1,000+ conditions and 100+ medication responses, includes board-certified genetic counseling, and reanalyzes your child's genome over time as science advances. See what Fore screens for.
FAQs
What is pharmacogenomics in simple terms?
Pharmacogenomics is the study of how a person's genes affect how their body processes and responds to medications. Certain gene variants change how quickly or effectively the body metabolizes specific drugs, which can influence whether a medication works as expected, causes side effects, or requires a different dose.
Is pharmacogenomic testing available for children?
Yes. Pharmacogenomic testing can be performed at any age, including infancy. Some clinical settings already use specific gene tests, such as TPMT testing before thiopurine therapy, as a routine part of prescribing. Broader pharmacogenomic profiling, as part of a whole genome screen, is also available and can be ordered by parents directly through at-home testing like Fore's screen.
Which genes are most important in pediatric pharmacogenomics?
CYP2D6, CYP2C19, and TPMT are among the most clinically studied genes in pharmacogenomics. CYP2D6 and CYP2C19 affect the metabolism of a wide range of medications. TPMT is particularly relevant for children who may be prescribed thiopurine-based therapies. Many other gene-drug pairs are also well characterized and can be identified through comprehensive screening.
Does my child's doctor already consider pharmacogenomics?
Some physicians incorporate pharmacogenomics into prescribing decisions, particularly in oncology and psychiatry. However, routine genetic testing before a first prescription is not yet universal. Having your child's pharmacogenomic profile on hand means that information is available whenever it becomes relevant, whether that is the first prescription or one years from now.
How is pharmacogenomics different from a standard drug allergy?
A drug allergy is an immune system reaction to a medication or one of its components. Pharmacogenomics is separate: it describes how efficiently the body metabolizes a drug, not whether the immune system reacts to it. A child can have no known drug allergies and still have a genetic variant that changes how their body handles a specific medication.